Subtype
Head and Neck Undifferentiated Carcinoma
CI-CAN-00002838Explore in graph →
26 active trials2 approved drugs5 evidence items
- NCIt
- C215427
Loading cancer entity…
Subtype
CI-CAN-00002838Explore in graph →
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer(NEO-COMBATXL) | recruiting | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 8, 2026 |
| clinicaltrials |
| NCT03975231 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | recruiting | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials